We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
-4%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$5M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$38.3M |
| 2 |
Amazon
AMZN
|
+$27.7M |
| 3 |
Palantir
PLTR
|
+$17.5M |
| 4 |
Hims & Hers Health
HIMS
|
+$13.7M |
| 5 |
Yum China
YUMC
|
+$13.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pinduoduo
PDD
|
+$39.4M |
| 2 |
NVIDIA
NVDA
|
+$30.1M |
| 3 |
Meta Platforms (Facebook)
META
|
+$14.9M |
| 4 |
KE Holdings
BEKE
|
+$14.1M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$11.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 42.45% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 8.06% |
| 5 | Consumer Staples | 5.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DAWN
501
DELISTED
Day One Biopharmaceuticals
DAWN
| $20.5K | ﹤0.01% |
2,582
+465
| +22% | +$5.01K |
|
|
CSR
502
Centerspace
CSR
$941M
| $20.3K | ﹤0.01% |
314
+38
| +14% | +$2.4K |
|
503
Mineralys Therapeutics
MLYS
$2.31B
| $20.2K | ﹤0.01% |
1,274
+229
| +22% | +$2.63K |
|
|
DEA
504
Easterly Government Properties
DEA
$1.15B
| $20.2K | ﹤0.01% |
760
+54
| +8% | +$1.49K |
|
505
Evolus
EOLS
$396M
| $19.5K | ﹤0.01% |
1,621
+291
| +22% | +$3.81K |
|
|
AVDL
506
DELISTED
Avadel Pharmaceuticals
AVDL
| $19.3K | ﹤0.01% |
2,467
+444
| +22% | +$3.72K |
|
507
Replimune Group
REPL
| $19.2K | ﹤0.01% |
1,970
+354
| +22% | +$4.38K |
|
508
Xencor
XNCR
$1.59B
| $19.1K | ﹤0.01% |
1,791
+322
| +22% | +$5.32K |
|
509
Anavex Life Sciences
AVXL
$250M
| $18.6K | ﹤0.01% |
2,171
+391
| +22% | +$3.69K |
|
510
Intellia Therapeutics
NTLA
$1.55B
| $18.5K | ﹤0.01% |
2,608
+469
| +22% | +$4.74K |
|
|
AAT
511
American Assets Trust
AAT
$1.48B
| $18.4K | ﹤0.01% |
915
+36
| +4% | +$812 |
|
|
LENZ
512
LENZ Therapeutics
LENZ
$181M
| $18.1K | ﹤0.01% |
704
+127
| +22% | +$3.13K |
|
513
Praxis Precision Medicines
PRAX
$8.58B
| $18.1K | ﹤0.01% |
477
+86
| +22% | +$5.37K |
|
514
Fortrea Holdings
FTRE
$1.81B
| $17.3K | ﹤0.01% |
2,296
+413
| +22% | +$5.83K |
|
|
PDM
515
Piedmont Realty Trust
PDM
$1.25B
| $17.1K | ﹤0.01% |
2,327
+91
| +4% | +$720 |
|
516
Prothena Corp
PRTA
$440M
| $17K | ﹤0.01% |
1,377
+247
| +22% | +$3.49K |
|
|
NXRT
517
NexPoint Residential Trust
NXRT
$677M
| $17K | ﹤0.01% |
429
+17
| +4% | +$672 |
|
518
Cogent Biosciences
COGT
$7.07B
| $16.9K | ﹤0.01% |
2,828
+509
| +22% | +$3.99K |
|
519
Arbutus Biopharma
ABUS
$871M
| $16.9K | ﹤0.01% |
4,852
+873
| +22% | +$2.91K |
|
520
AbCellera Biologics
ABCL
$1.74B
| $16.9K | ﹤0.01% |
7,563
+1,361
| +22% | +$3.9K |
|
|
SAFE
521
Safehold
SAFE
$1.13B
| $16.3K | ﹤0.01% |
871
+34
| +4% | +$597 |
|
522
ArriVent BioPharma
AVBP
$1.43B
| $16K | ﹤0.01% |
863
+155
| +22% | +$3.79K |
|
|
CVAC
523
DELISTED
CureVac
CVAC
| $15.9K | ﹤0.01% |
5,744
+1,034
| +22% | +$3.6K |
|
524
Rocket Pharmaceuticals
RCKT
$351M
| $15.6K | ﹤0.01% |
2,333
+419
| +22% | +$4.14K |
|
525
AnaptysBio
ANAB
$1.63B
| $14.5K | ﹤0.01% |
779
+140
| +22% | +$2.34K |
|
Similar funds
CM
BP
AAM
CAG
RCG
AL
CGPCS
EAM
GF Fund Management's Q1 2025 Portfolio in Review
As of Q1 2025, GF Fund Management held 683 positions worth $4.26B, down 7.8% from $4.62B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
GF Fund Management's Q1 2025 filing shows 46 new, 475 increased, 93 reduced and 17 closed positions. Its largest new stake was Hims & Hers Health: 368,661 shares worth $10.9M. The largest sale was Pinduoduo, an estimated $39.4M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, down from 45% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q1 2025 buy was Hims & Hers Health: 368,661 shares worth $10.9M.
- GF Fund Management added most to Philip Morris in Q1 2025, an estimated $38.3M increase.
- GF Fund Management's biggest Q1 2025 reduction was Pinduoduo, cutting an estimated $39.4M.
- GF Fund Management fully exited Applied Optoelectronics in Q1 2025, selling an estimated $5.07M.
- GF Fund Management's ten largest holdings make up 44% of its $4.26B portfolio in Q1 2025.
- GF Fund Management opened 46 new positions and closed 17 in Q1 2025.
- GF Fund Management's portfolio value fell 7.8% quarter-over-quarter to $4.26B.
Based on GF Fund Management's 13F filing for Q1 2025, filed 29 Apr 2025.